Health
New Data from Sumitomo Pharma America at AUA 2026 Highlight Efficacy of Vibegron in Men Aged 75 and Older with Overactive Bladder and BPH
MARLBOROUGH, Mass., May 18, 2026--Sumitomo Pharma America, Inc. (SMPA) today announced the presentation of new data from its urology and oncology portfolios at the American Urological Association (AUA) 2026 Annual Meeting, held on May 15–18 in Washington, D.C. The presentations include a featured subgroup analysis of the phase 3 COURAGE trial evaluating vibegron in older men, along with real-world evidence from the OPTYX study of relugolix in advanced prostate cancer.
About this update from Sumitomo Pharma Co.ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":4559,"height":612,"url":"https://media.zenfs.com/en/business-wire.com/bec0f7a95e23b24a78c31ff1449fecce"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/UPYMcvaP8aHmylb0DwSmqA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTEyOQ--/https://media.zenfs.com/en/business-wire.com/bec0f7a95e23b24a78c31ff1449fecce","width":960,"height":129},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/zGaucKiWAkvdWq7QSJQ0tg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTg2/https://media.zenfs.com/en/business-wire.com/bec0f7a95e23b24a78c31ff1449fecce","width":640,"height":86},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/VHKJE8TFiFmI1w9tw7FFXg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zMjI-/https://media.zenfs.com/en/business-wire.com/bec0f7a95e23b24a78c31ff1449fecce","width":1200,"height":161}},"lazy":false},{"type":"text","content":"SMPA reinforces commitment to the urology community with findings from studies across overactive bladder and advanced prostate cancer portfolios","length":144,"tagName":"p","attribs":{}},{"type":"text","content":"MARLBOROUGH, Mass., May 18, 2026--(BUSINESS WIRE)--Sumitomo Pharma America, Inc. (SMPA) today announced the presentation of new data from its urology and oncology portfolios at the American Urological Association (AUA) 2026 Annual Meeting, held on May 15–18 in Washington, D.C. The presentations include a featured subgroup analysis of the phase 3 COURAGE trial evaluating vibegron in older men, along with real-world evidence from the OPTYX study of relugolix in advanced prostate cancer.","length":489,"tagName":"p"},{"type":"text","content":""Our presence at AUA 2026 underscores our deep-rooted commitment to advancing scientific understanding for patients managing complex urologic conditions," said Tsutomu Nakagawa, Ph.D., President and Chief Executive Officer of SMPA. "By focusing on patient populations at particular risk, such as men over 75 with overactive bladder and on pharmacologic treatment for benign prostatic hyperplasia, and those navigating the complexities of advanced prostate cancer, we aim to provide clinicians with the robust data they need to make informed, patient-centered treatment decisions."","length":600,"tagName":"p"},{"type":"text","content":"Safety and e...